Evidence map›Paper›PMID 40790609›Full record

ArticleTrials2025

Nitric oxide for the prevention of postoperative acute kidney injury in patients undergoing surgery for Stanford type A aortic dissection: study protocol for a randomized controlled trial.

Zheyuan Chen, Xiao Han, Lingru Li, Maomao Liu, Li Yu, Sihao Cheng, Yan Yu, Nan Liu

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06622291 (Efficacy of Nitric Oxide Administration for Reducing the Risk of Acute Kidney Injury in Patients With Acute Type A Aortic Dissection), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06622291 phase4completednot on this map

Efficacy of Nitric Oxide Administration for Reducing the Risk of Acute Kidney Injury in Patients With Acute Type A Aortic Dissection: a Randomized Controlled Trial

TypeinterventionalSponsorBeijing Anzhen HospitalRan2024 to 2026Enrolled106ConditionsAcute Kidney Injury, Nitrous Oxide, Acute Type A Aortic DissectionArmsNitric Oxide, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zheyuan ChenCenter for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Xiao HanDepartment of Emergency, University of Health and Rehabilitation (Qingdao Municipal Hospital), Qingdao , Qingdao Hospital, 266000, China.
Lingru LiCenter for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Maomao LiuCenter for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Li YuCenter for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Sihao ChengCenter for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Yan YuCenter for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Nan LiuCenter for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. ln9102@126.com.

Funding

Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park No. Z191100006619095
6 · The paper itself

Abstract

backgroundAcute kidney injury (AKI) is a frequent and serious complication following surgery for acute type A aortic dissection (ATAAD). Nitric oxide (NO) may reduce AKI incidence through renal-protective mechanisms, but evidence in the ATAAD population remains limited. This trial aims to evaluate whether perioperative administration of NO can reduce the incidence of postoperative AKI in this population.

methodsThis single-center, randomized, parallel-group superiority trial will enroll 106 adult patients undergoing ATAAD emergency surgery. Participants will be randomly allocated in a 1:1 ratio to either receive 60 parts per million of NO during cardiopulmonary bypass and for 12 h post-surgery, or to receive standard care without NO. The primary outcome is AKI incidence within 48 h postoperatively, defined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Secondary outcomes include AKI severity, urine output, vasoactive-inotropic score, neutrophil gelatinase-associated lipocalin levels, sequential organ failure assessment score, ventilator support duration, intensive care unit (ICU) and hospital length of stay, and major adverse kidney events, cumulative mediastinal and pericardial drainage volume. DISCUSSION: This trial will evaluate whether perioperative NO administration can reduce early AKI and improve renal and clinical outcomes in high-risk ATAAD patients. Findings may provide evidence for a novel nephroprotective strategy in aortic surgery.

trial registrationClinicalTrials.gov NCT06622291. Registered on June 26, 2024.

Indexed as

Acute Kidney InjuryAortic AneurysmAortic DissectionNitric OxidePostoperative ComplicationsAdultCardiopulmonary BypassEquivalence Trials as TopicFemaleHumansIncidenceMaleMiddle AgedRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeNitric OxideAcute kidney injuryAortic dissectionCardiac surgeryNitric oxideRandomized controlled trial

Identifiers

PMID40790609
PMCPMC12341110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.